568 related articles for article (PubMed ID: 10604050)
1. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis.
Kole L; Das L; Das PK
J Infect Dis; 1999 Sep; 180(3):811-20. PubMed ID: 10438370
[TBL] [Abstract][Full Text] [Related]
3. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
Pal S; Ravindran R; Ali N
Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
[TBL] [Abstract][Full Text] [Related]
5. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis.
Raay B; Medda S; Mukhopadhyay S; Basu MK
Indian J Biochem Biophys; 1999 Aug; 36(4):248-51. PubMed ID: 10650726
[TBL] [Abstract][Full Text] [Related]
6. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
7. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
Badaro R; Falcoff E; Badaro FS; Carvalho EM; Pedral-Sampaio D; Barral A; Carvalho JS; Barral-Netto M; Brandely M; Silva L
N Engl J Med; 1990 Jan; 322(1):16-21. PubMed ID: 2104665
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes.
Hockertz S; Franke G; Paulini I; Lohmann-Matthes ML
J Interferon Res; 1991 Jun; 11(3):177-85. PubMed ID: 1919076
[TBL] [Abstract][Full Text] [Related]
9. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
Sinha R; Roychoudhury J; Palit P; Ali N
Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
[TBL] [Abstract][Full Text] [Related]
10. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis.
Mukherjee S; Das L; Kole L; Karmakar S; Datta N; Das PK
J Infect Dis; 2004 Mar; 189(6):1024-34. PubMed ID: 14999606
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
Murray HW
Acta Trop; 2005 Mar; 93(3):295-301. PubMed ID: 15716043
[TBL] [Abstract][Full Text] [Related]
12. Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
Reed SG; Barral-Netto M; Inverso JA
J Immunol; 1984 Jun; 132(6):3116-9. PubMed ID: 6725947
[TBL] [Abstract][Full Text] [Related]
13. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
14. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo.
Morishige K; Aji T; Ishii A; Yasuda T; Wataya Y
Exp Parasitol; 1995 Jun; 80(4):665-71. PubMed ID: 7758547
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
18. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
Murray HW; Montelibano C; Peterson R; Sypek JP
J Infect Dis; 2000 Nov; 182(5):1497-502. PubMed ID: 11023473
[TBL] [Abstract][Full Text] [Related]
20. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine.
Tempone AG; Perez D; Rath S; Vilarinho AL; Mortara RA; de Andrade HF
J Antimicrob Chemother; 2004 Jul; 54(1):60-8. PubMed ID: 15163652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
